European Journal of Dermatology


Successful treatment of adalimumab-induced paradoxical psoriatic arthritis with risankizumab Volume 30, numéro 5, September-October 2020


  • Figure 1
Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahabacho, Iwate 028-3695, Japan

Tumour necrosis factor (TNF)α inhibitors are widely used for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, one undesired effect is psoriasiform and palmoplantar pustulosis (PPP)-like eruption, also known as “paradoxical reaction” [1]. Although in most affected patients, it is possible to continue TNFα inhibitors with conventional therapy, some patients need to be switched to different biologic agents because of severe skin [...]